State Board of Administration of Florida Retirement System grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,426 shares of the company’s stock after buying an additional 810 shares during the period. State Board of Administration of Florida Retirement System owned 0.14% of Neurocrine Biosciences worth $7,380,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of NBIX. Teachers Advisors LLC lifted its holdings in Neurocrine Biosciences by 5.6% in the 1st quarter. Teachers Advisors LLC now owns 82,647 shares of the company’s stock worth $3,579,000 after purchasing an additional 4,360 shares in the last quarter. Legal & General Group Plc lifted its holdings in Neurocrine Biosciences by 213.4% in the 1st quarter. Legal & General Group Plc now owns 29,305 shares of the company’s stock worth $1,269,000 after purchasing an additional 19,955 shares in the last quarter. BlackRock Inc. lifted its holdings in Neurocrine Biosciences by 14,216.0% in the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in Neurocrine Biosciences by 5.6% in the 1st quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock worth $626,000 after purchasing an additional 763 shares in the last quarter. Finally, Aperio Group LLC lifted its holdings in Neurocrine Biosciences by 3.7% in the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after purchasing an additional 789 shares in the last quarter.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $75.46 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm posted ($0.43) EPS. equities research analysts anticipate that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/state-board-of-administration-of-florida-retirement-system-has-7-38-million-stake-in-neurocrine-biosciences-inc-nbix/1699942.html.

In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the transaction, the insider now owns 55,898 shares of the company’s stock, valued at approximately $3,412,013.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the transaction, the insider now directly owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,810 shares of company stock worth $6,797,998. Corporate insiders own 4.80% of the company’s stock.

A number of research analysts recently commented on NBIX shares. Robert W. Baird reissued an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group LLC reissued a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Leerink Swann reissued an “outperform” rating and issued a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Cowen and Company reissued an “outperform” rating and issued a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Finally, Barclays PLC boosted their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $78.88.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.